Background: Dermatofibrosarcoma protuberans (DFSP) is a tumor of intermediate malignancy,
| t(17;22) COL1A1-PDGFB FISH for diagnosis of DFSP
DFSP is a distinctive slow-growing dermal and subcutaneous tumor of intermediate malignancy. Patients are typically in their early or middle adulthood. Tumors have a predilection for the trunk, proximal extremities, and head/neck region. 1 Grossly, the tumor appears as a wellcircumscribed gray-white nodule involving the dermis and subcutis.
Microscopically, despite its apparent gross circumscription, the tumor diffusely infiltrates the dermis and subcutis. DFSP is composed of uniform monomorphic spindle cells arranged in a distinctive storiform or cartwheel pattern. There is little nuclear pleomorphism and no significant mitotic activity. 2 By immunohistochemistry DFSP typically expresses CD34 and is negative for factor XIIIa and S100 protein.
The most common and challenging differential diagnoses for DFSP are represented by the deep and cellular variants of dermatofibroma. In contrast to cellular dermatofibroma, DFSP is characterized by a larger size, infiltrative pattern within the subcutis and uniform morphology while typically lacking secondary elements such as giant cells, xanthoma cells, or inflammatory cells. Another common differential diagnosis is the diffuse variants of neurofibroma. In this case, the lower cellularity and positive staining for S100 seen in neurofibroma allows for the differentiation from DFSP. 3 Variations from the classic histology are seen in pigmented DFSP (Bednar tumor) and DFSP with areas of fibrosarcomatous change. Uncommon histologic variants include DFSP with myxoid changes, which may cause confusion with a myxoid liposarcoma, DFSP with areas of undifferentiated pleomorphic sarcoma, DFSP resembling a vascular tumor, DFSP with myoid nodules, and the sclerotic variant of DFSP. [3] [4] [5] [6] [7] DFSP is a tumor of intermediate malignancy with low metastatic potential, but locally aggressive behavior. Historically, recurrence rates are reported to be as high as 50%; however, more recent studies show an overall recurrence rate of 7.3%. 8, 9 The presence of fibrosarcomatous areas indicates a more aggressive behavior with higher potential for metastasis. 10 Wide local excision is the treatment of choice.
Cytogenetically, DFSP is characterized by a balanced or unbalanced t(17;22)(q22;q13) translocation or a supernumerary ring chromosome, resulting in the fusion of exon 2 of PDGFB gene encoding the platelet-derived growth factor beta with various exons (from 6 to 47) of COL1A1 gene encoding the alpha chain type 1 collagen. [11] [12] [13] [14] Interestingly, the same rearrangement was demonstrated in giant cell fibroblastoma (GCF), a tumor developing in children that is now considered to represent a juvenile form of DFSP. 15 The ring chromosome is more common in adult cases of DFSP while the linear translocation tends to occur in children and is prevalent in GCF. 14, 15 The translocation deletes exon 1 of PDGFB and puts the gene under control of the COL1A1 gene promoter, compromising the physiological regulation of this factor. This results in overexpression of PDGFB, which enables downstream signaling through the PDGFB receptor and MAP-kinase pathway. 13 In addition, this alteration renders the tumor sensitive to imatinib mesylate, which is now used for the treatment of inoperable or metastatic disease. [16] [17] [18] The t (17;22) Although it shares clinical, histologic, immunohistochemical, molecular, and ultrastructural features with melanoma, CCS is considered to be a distinct entity that is separate from cutaneous melanoma. [23] [24] [25] Distinction between these two entities is crucial as the treatment modality and prognosis are different. CCS typically occurs in adolescents and young adults (third to fourth decades of life) with a slight female predominance and preferentially arises in the deep soft tissue of tendons, aponeuroses, and fascial structures of the distal extremities. It is associated with a high propensity for multiple local recurrences with late metastases and a high death rate. [26] [27] [28] It is one of the few sarcomas with a high propensity for lymph node metastases, which are present in up to 50% of cases. 29 Histologically typical cases of CCS are characterized by a nested or fascicular growth pattern of fusiform and/or epithelioid cells with clear to finely granular cytoplasm and prominent nucleoli. 30 Delicate fibrous septa encase the cellular aggregates and in two thirds of cases multinucleated cells are observed. 31 Immunohistochemically, virtually all CCSs express S100 protein diffusely and most are also positive for Melan-A, HMB45, and MiTF similar to cutaneous melanomas. 30 Melanin pigment can be detected either by hemotoxylin and eosin (H&E) or with appropriate histochemical stains (eg, Fontana-Masson) and melanosomes can be seen in varying stages of development using electron microscopy. 32 BRAF/ NRAS mutations, which are present in~50% to 60% of melanomas, have also been rarely detected in CCSs. 33, 34 Superficial cutaneous examples are well documented in the literature. 31, 35, 36 In these instances, the tumor is dermal-based with potential subcutaneous extension. In addition, rare cases with a junctional component mimicking melanoma in situ have also been reported. 37, 38 Consequently, CCS can be confused with cutaneous spindle-cell melanoma or metastatic melanoma, with significant prognostic and predictive repercussions for the patient.
CCS has a characteristic translocation that most commonly fuses A search for journal articles written in English was performed in PubMed using keywords "dermatofibrosarcoma" combined with either "FISH," "fluorescence in situ," "translocation," "fusion," "COL1A1," or "PDGFB" and a date range from 2000 to present ( 56 and another used dermal dendrocyte hamartoma, a mimic of DFSP. 50 In all studies, the dual fusion FISH test performed with a specificity of 100%. Data regarding the rate of test failure for dual fusion FISH could be derived from 10 studies, [4] [5] [6] 19, 43, [45] [46] [47] 49, 52 which showed an overall test failure frequency of 8.12%. In most cases, the reason for test failure was determined to be inappropriate fixation or use of a fixative other than formalin. 46 From the six studies evaluating the PDGFB break-apart FISH test, the overall sensitivity was 95% (range: 91%-100%). There was no data available to determine the specificity of the PDGFB break-apart FISH test. The overall failure rate for this test was 3.22%. Only one study evaluated the COL1A1 break-apart probe in DFSP with a sensitivity of 100%. 20 In three studies, RT-PCR was performed in parallel with FISH. 19, 51, 56 The overall sensitivity for RT-PCR was 72.53% and the incidence of failed tests was 17.69%.
In a prospective study by Karanian et al, 448 consecutive tumors suspected to be DFSP were subjected to FISH testing using dual fusion FISH. 46 All tumors were subclassified as certain (200 cases Of these, eight cases were locally advanced cases and two cases were metastatic cases. FISH was positive in nine cases, all of which demonstrated either total (four cases) or partial (five cases) response to therapy. One case was negative by FISH and showed no response to imatinib. 18 In a study by Kerob et al, 21 of 25 DFSP patients with COL1A1-PDGFB rearrangement 9 (38%) achieved complete or partial response, while none of the 2 patients without the translocation responded to imatinib therapy. 47 
| Dual color break-apart EWSR1 FISH in differentiating melanocytic tumors from CCS
Because of the rarity of CCS, the date range was not limited when performing the literature search for dual-color break-apart EWSR1
FISH for differentiating melanocytic tumors from CCS ( Table 2 ). The translocation was first identified in 1990. A search for journal articles written in English was performed in PubMed and only case reports with scientifically sound evidence of molecular testing were included.
Articles addressing visceral CCS (gastrointestinal, pulmonary, and renal) were excluded.
We identified 18 relevant articles, all retrospective studies, that are summarized in Table 2 . 30, 31, 33, 34, 36, 40, [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] The overall number of patients was 234, which included 236 samples analyzed. As expected, a significant proportion of cases were from acral sites (46.67%, 91/195) and the majority of patients (83%) were less than 50 years of age (171/206). Only a few cases reported the sarcoma having a component "mimicking junctional nests"; one case remarked on a junctional component. 37 Most series used melanoma cases or melanoma cell lines as negative controls with the exception of one study that compared many different types of sarcoma. 24 The overall sensitivity of dual-color break-apart EWSR1 FISH was 88.89% and the specificity 97.91%; the test failed for various reasons in 6.33% of cases. The sensitivity of the dual fusion test was 60%, whereas its specificity was 100%. There were no data available regarding the percentage of failed Other findings
• Most series used melanoma cases or melanoma cell lines as negative controls for tests (except one study which compared many different types of sarcoma) • Few cases reported with areas "mimicking junctional nests", one case with reported junctional component • BRAF mutation + in 4.55% cases, NRAS mutation + in 4.55% cases • One study looked at deep tumors previously called melanoma and found EWSR1 rearrangements in 2 of 18 cases (11.11%)
Abbreviations: CCS, clear cell sarcoma; FISH, fluorescence in situ hybridization; RT-PCR, reverse-transcriptase PCR.
tests. The sensitivity for RT-PCR was 91.61% and the specificity was 100%; RT-PCR failed in 22.22% of cases.
In one of the first series after the discovery of the translocation, This study also demonstrated that none of the CCS cases displayed microsatellite instability (MSI). One CCS case did have loss of heterozygosity of 9p21, raising the question if the lesion should be better classified as a melanocytic/spitzoid tumor.
Another study described two purely cutaneous cases. 31 Six cases were entirely dermal, whereas the other six showed invasion of the subcutis. In six cases, the nests bordered the epidermis mimicking junctional nests of melanocytes although "true nests" were not identified. Falconieri et al also reported three cases of dermal CCS with minimal extension to the subcutis all of which were confirmed by EWSR1
FISH. 36 In one other large study from a tertiary center, FISH and RT-PCR results on a variety of sarcoma cases, including CCS, were reviewed. 64 The study highlights the difficulties that arise when the methods of tissue fixation and processing of referral blocks are not certain resulting in higher RT-PCR failure rates.
Song et al subjected 18 cases with malignant melanoma diagnosis from non-cutaneous, deeply located sites and unknown primary sites to break-apart EWSR1 FISH. 65 They identified two patients with In a retrospective study of 52 patients with CCS, Hocar et al identified 1 of 22 tested cases with a BRAF mutation and 1 of 22 tested cases with a NRAS mutation 33 ; both cases were confirmed using RT-PCR. Park et al also described two cases of CCS, one dermal, and one subcutaneous, which were confirmed using FISH and RT-PCR. 34 BRAF mutation was detected in the dermal type and KIT mutation in the subcutaneous one raising interesting questions regarding treatment options.
Lastly, Ito et al reported an exceedingly rare case of CCS in the penis 68 whereas Feasel et al described three cases in the head and neck expanding the anatomic distribution. 3 | COMMENTS AND CONCLUSIONS
| Current utilization
An audience response system was used to identify the current utilization patterns of ordering FISH for DFSP and CCS. Basic demographic information of the participants revealed that the majority of respondents are in an academic practice setting (47% with only two probes flanking a gene vs the latter with at least four probes flanking two genes which increases the likelihood that one or more probes will fail hybridization. However, the difference could also be related to differences in study format. In the series of studies on break-apart FISH, only one study explicitly reported the failure rate vs four studies reporting this information in the dual fusion FISH cohort.
As expected, RT-PCR showed a lowered sensitivity (73%) and higher rate of failed tests (18%) compared to FISH, probably due to the challenges in obtaining good quality RNA from formalin-fixed paraffinembedded material.
The data suggests that FISH testing has limited value in classic DFSP as the overwhelming majority would be positive for 
| EWSR1 break-apart FISH in differentiating melanocytic tumors from CCS
The review of the literature indicates that the fusion (either EWS-R1-ATF1 or EWSR1-CREB1) is present in the majority of cases of CCS, whereas no melanomas were identified to harbor these translocations.
Given the high sensitivity and specificity of the dual-color break-apart FISH test in this clinical scenario and the significant consequences of a misdiagnosis the literature supports the use of dual-color breakapart EWSR1 FISH to differentiate CCS from melanoma or other melanocytic neoplasms. This is reflective of the current practice of respondents attending the short course as the majority (69%) would order the test to support the diagnosis with an addition 17% doing so after contacting the referring clinician.
